Andrew Berchuck, MD

Co-Director, Duke Comprehensive Cancer Center, Breast/Ovarian Cancer Program
Duke University

For the past 35 years Dr. Berchuck has been actively involved in caring for women with gynecologic cancers on a daily basis while also leading a nationally recognized program in translational research related to the molecular origins of ovarian cancer. He has served in many roles related to ovarian cancer translational research including being a member of the TCGA ovarian and endometrial cancer working groups and chairing two study sections for the Department of Defense Ovarian Cancer Research Program. He also led the scientific advisory board of the Ovarian Cancer Research Fund for 8 years. With his epidemiology colleague Joellen Schildkraut, PhD, he has been one of the leaders of the North Carolina Ovarian Cancer Study, which seeks to identify common genetic polymorphisms that affect ovarian cancer susceptibility. In 2005 he was one of the founding members of the Ovarian Cancer Association Consortium (OCAC), an international group of over 100 studies collaborating to validate the results of genetic association studies in ovarian cancer. For 17 years he served as head of the OCAC steering committee during a time when OCAC identified 35 genome-wide significant SNPs associated with ovarian cancer risk. He has extensive experience in the field of hereditary cancer genetics and has been actively involved in managing patients with high penetrance mutations that predispose to ovarian and endometrial cancer. In 2022 he was appointed as one of the medical directors of the Duke Clinical Cancer Genetics Program. Dr. Berchuck has been involved in national activities related to ovarian cancer, including serving as President of the Society of Gynecologic Oncology in 2007. He is also a member of the NCCN ovarian cancer guidelines committee.